Treatment with immunotherapy alone produces ‘exceptional’ response rates in some melanoma patients
COLUMBUS, Ohio ­– Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
Desmoplastic melanoma is a subset of melanoma skin cancer that is caused by high levels of ultraviolet (UV) radiation damage and, therefore, a high number of tumor mutations that all contribute to aggressive ...







